lncRNA MALAT1 Promotes Diabetic Nephropathy Progression via miR-15b-5p/TLR4 Signaling Axis

Zijun Yang1, Dongxu Song1, Yulin Wang1

  • 1Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Abstract

Insights

Reduced MALAT1 lessens high glucose-induced kidney cell damage by inhibiting the miR-15b-5p/TLR4 pathway. This suggests MALAT1 is a potential therapeutic target for diabetic nephropathy (DN).

Area of Science:

  • Molecular Biology
  • Renal Pathophysiology
  • RNA Biology

Background:

  • Diabetic nephropathy (DN) pathogenesis is linked to long noncoding RNA MALAT1.
  • The precise molecular mechanisms of MALAT1 in DN remain unclear.
  • Investigating MALAT1's role in DN is crucial for developing new therapies.

Purpose of the Study:

  • To elucidate the mechanism of MALAT1 in diabetic nephropathy (DN).
  • To investigate the regulation of miR-15b-5p/TLR4 signaling by MALAT1 in DN.
  • To explore MALAT1 as a potential therapeutic target for DN.

Main Methods:

  • Collected human DN renal tissues and utilized high glucose-induced HK-2 cells as a DN model.
  • Assessed cell viability, apoptosis, and inflammatory cytokines following MALAT1 knockdown.
  • Validated interactions using dual-luciferase reporter assays and RNA immunoprecipitation (RIP).

Main Results:

  • MALAT1 was significantly upregulated in DN tissues and high glucose-stimulated HK-2 cells.
  • MALAT1 knockdown attenuated high glucose-induced cell damage and inflammation.
  • miR-15b-5p inhibition or TLR4 overexpression reversed the protective effects of MALAT1 knockdown.

Conclusions:

  • Reduced MALAT1 ameliorates high glucose-induced kidney cell damage via the miR-15b-5p/TLR4 axis.
  • MALAT1 inhibition presents a potential therapeutic strategy for diabetic nephropathy.
  • MALAT1 may serve as a valuable biomarker for DN.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.5K